A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison

Trial Profile

A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Tazarotene (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Sponsors Almirall Hermal GmbH
  • Most Recent Events

    • 09 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2014 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health - NCT02235480).
    • 09 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top